Smartwatch-based lifestyle program for heart health in people with overweight or obesity
Tests a smartwatch-led diet and exercise program in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: Smartwatch-based Intervention for Cardiovascular Health (SWITCH)
Key facts
- Where
- Beijing, Cangzhou, and Yuhuan, ChinaSee the 3 sites
Where in China
- Beijing Chao-Yang HospitalBeijing, ChinaTaking people
- Cangzhou Central HospitalCangzhou, ChinaTaking people
- Health Community Group of Yuhuan People's HosptialYuhuan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Anzhen Hospital
- Trial code
- NCT07372729
- Record updated
- 29 October 2026
- Original description
This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among metabolically at-risk people with overweight/obesity, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.Read full original descriptionShow less
Smartwatch-based Multifaceted Behavioral Intervention for Improving Cardiovascular Health in Metabolically At-risk People With Overweight/Obesity in Chinese Primary Healthcare Settings (SWITCH): a Cluster Randomized Controlled Trial
This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among metabolically at-risk people with overweight/obesity, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.
Inclusion: Age >= 18 years, no gender restriction; Overweight and obesity: Body Mass Index (BMI) 24.0-32.4 kg/m\^2, or waist circumference >= 90 cm for males and >= 85 cm for females; Presence of at least one metabolic high-risk state among high-normal blood pressure, prediabetes, or borderline elevated blood lipids, and without a diagnosis of hypertension, diabetes mellitus, or dyslipidemia:; (1) High-normal BP: Systolic blood pressure (SBP) 120-139 mmHg and/or diastolic blood pressure (DBP) 80-89 mmHg, without regular use of antihypertensive medication in the past month; (2) Prediabetes: Fasting blood glucose (FBG) 6.1-6.9 mmol/L, or glycated hemoglobin (HbA1c) 5.7%-6.4%, without regular use of hypoglycemic medication in the past month; (3) Borderline elevated blood lipids: Total cholesterol (TC) 5.2-6.1 mmol/L, or low-density lipoprotein cholesterol (LDL-C) 3.4-4.0 mmol/L, or triglycerides (TG) 1.7-2.2 mmol/L, or non-high-density lipoprotein cholesterol (non-HDL-C) 4.1-4.8 mmol/L, without regular use of lipid-lowering medication in the past month; 4. Local permanent residents who will reside in the area for at least 12 month after enrollment; 5. Have basic reading, writing, and comprehension abilities; proficient in using internet-connected smartphones; able to independently complete basic operations of the application; 6. Written informed consent provided.
Exclusion: Cardiovascular and cerebrovascular diseases, including myocardial infarction, stroke, heart failure, arrhythmia; or having received coronary intervention therapy, cardiac surgery, etc.; or with a 10-year high risk of cardiovascular disease; Individuals undergoing or planning to receive weight loss through surgery, medication, or other methods; Diseases seriously affecting survival, such as malignant tumors, AIDS, hepatic and renal failure; History of severe neuropsychiatric diseases with potential cognitive or communication impairments, such as dementia, Alzheimer's disease, Parkinson's syndrome; Secondary obesity diagnosed by doctors in secondary or higher-level medical institutions; Pregnancy, lactation period, or women who may become pregnant within one year; Individuals with limited daily mobility; Currently participating in other lifestyle intervention-related trials.